(Q34121326)

31 July 2017

title

Anti-α-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry (English)

1 reference

31 July 2017

1 reference

Dominique P Germain

3

0 references

David G Warnock

11

object named as

David G Warnock

1 reference

31 July 2017

4

Ulla Feldt-Rasmussen

1 reference

31 July 2017

William R Wilcox

1

1 reference

31 July 2017

Gabor E Linthorst

2

1 reference

31 July 2017

Stephen Waldek

5

1 reference

31 July 2017

Susan M Richards

6

1 reference

31 July 2017

Dana Beitner-Johnson

7

1 reference

31 July 2017

Marta Cizmarik

8

1 reference

31 July 2017

J Alexander Cole

9

1 reference

31 July 2017

Wytske Kingma

10

1 reference

31 July 2017

publication date

14 December 2011

1 reference

Molecular Genetics and Metabolism

31 July 2017

published in

1 reference

31 July 2017

volume

105

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

443-449

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

31 July 2017

1 reference

Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

End-stage renal disease in patients with Fabry disease: natural history data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Fabry disease: progression of nephropathy, and prevalence of cardiac and cerebrovascular events before enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Agalsidase-beta therapy for advanced Fabry disease: a randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Human immune response to recombinant human proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Neutralizing antibodies to therapeutic enzymes: considerations for testing, prevention and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Liquid chromatography-tandem mass spectrometry quantification of globotriaosylceramide in plasma for long-term monitoring of Fabry patients treated with enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Evaluation of a low dose, after a standard therapeutic dose, of agalsidase beta during enzyme replacement therapy in patients with Fabry disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Enzyme replacement therapy in Fabry disease: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2011.12.006

10.1016/J.YMGME.2011.12.006

7 January 2021

Identifiers

DOI

1 reference

31 July 2017

1 reference